Epha2 bite molecules and uses thereof

Details Epha2 bite molecules and uses thereof Epha2 bite molecules and uses thereof

C - Chemistry, Metallurgy

07

K

C07K 16/46 (2006.01) A61K 39/395 (2006.01) A61P 31/00 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01) C07K 16/40 (2006.01) C12N 15/13 (2006.01)

Patent

CA 2633713

The present invention relates to bispecific single chain antibodies comprising a first binding domain that irnmunospecifEcally binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term "EphA2-BiTEs." The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expres-sion and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2 -BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs. The invention also provides compositions, including pharmaceutical compositions, comprising any of the aforementioned EphA2-BiTEs, polynucleotides or vectors either alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are methods of screening for said EphA2-BiTEs and kits comprising any of the aforementioned compositions and diagnostic reagents.

La présente invention concerne des anticorps monocaténaires bispécifiques comprenant un premier domaine de liaison se liant immuno-spécifiquement à l'antigène CD3 des lymphocytes T et un second domaine de liaison se liant immuno-spécifiquement au récepteur EphA2. De tels anticorps monocaténaires bispécifiques sont regroupés sous le terme EphA2-BiTEs'. La présente invention concerne en outre des procédés et des compositions destinés au traitement, à la prévention et/ou à la gestion des troubles associés à l'expression aberrante et/ou l'activité de EphA2. De tels troubles comprennent, à titre indicatif et non exhaustif, le cancer, les troubles cellulaires hyperprolifératifs non cancéreux et des infections. La présente invention concerne en outre des vecteurs comprenant des polynucléotides codant les EphA2 -BiTEs selon l'invention, des cellules hôtes transformées grâce à ceux-ci et leur utilisation dans la production desdits EphA2-BiTEs. L'invention concerne également des compositions, y compris des compositions pharmaceutiques, comprenant l'un quelconque des EphA2-BiTEs susmentionnés, des polynucléotides ou des vecteurs seuls ou en combinaison avec un ou plusieurs agents prophylactiques ou thérapeutiques. L'invention concerne en outre des procédés de criblage pour lesdits EphA2-BiTEs et des kits comprenant l'une quelconque des compositions susmentionnées et des réactifs diagnostiques.

Affiliated with

Also associated with

Rating

Epha2 bite molecules and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epha2 bite molecules and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epha2 bite molecules and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1489551